Navigation Links
AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations
Date:2/16/2009

RESEARCH TRIANGLE PARK, N.C., Feb. 16 /PRNewswire/ -- AlphaVax announced today that it has hired Lynn Baird, PhD, as Vice President of Regulatory, Quality and Clinical Operations. In this capacity Lynn will provide leadership and strategic direction in the areas of regulatory and quality affairs and in clinical operations.

"Lynn's experience in directing successful clinical trials, developing regulatory strategy and gaining regulatory approval for clinical trials will complement our existing leadership team. We will look to Lynn to manage the regulatory affairs for in-house programs at AlphaVax as they move through clinical development, as well as coordinate and support regulatory activities of corporate partners involved with our alphavirus vector platform," said Andrew Graham, Vice President of Development at AlphaVax.

Most recently, Lynn was Sr. Vice President, Regulatory, Quality and Clinical Operations with CombinatoRx, Inc. in Cambridge, MA. Previous to that appointment, she held executive management positions for regulatory affairs and quality at Dyax, Curis and CytoTherapeutics. Lynn earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University in Richmond, Virginia.

"We are truly delighted to attract someone of Lynn's caliber, capability and expertise. There is no doubt that she will play a significant role in our future growth and success as we advance multiple vaccine products through clinical development," said Jonathan Gelles, Chairman of AlphaVax's Board of Directors.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company's business strategy is to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for influenza, cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is located in Lenoir, NC.


'/>"/>
SOURCE AlphaVax
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Announces New Name for Spinoff Company
2. ATS Medical Announces Fourth Quarter 2008 Earnings Release Date and Conference Call
3. URAC Announces Agenda for 2009 Best Practices in Health Care Consumer Empowerment and Protection Conference
4. Hill-Rom Announces Second Quarter 2009 Dividend
5. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
6. Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International
7. QLT announces that it is named as a defendant in an action
8. Biotel Announces Profitable Second Quarter Ended December 31, 2008
9. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
10. Investor Group Commends Jim Merselis for Joining Trinity Biotechs Board of Directors & Announces Conference Call Invitation
11. Cogdell Spencer Announces Dorr as President of the Southeast Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: